© 2017 Pharmstandard Ventures
AquinoxPharmaceuticals
(NASDAQ:AQXP)
Vancouver, Canada
Year of Investment: 2013
(NASDAQ:AQXP)
Vancouver, Canada
Year of Investment: 2013
Year of Exit: 2015-2016
IPO in March, 2014
IPO in March, 2014
Aquinox
Pharmaceuticals
(NASDAQ:AQXP)
Vancouver, Canada
Year of Investment: 2013
Pharmaceuticals
(NASDAQ:AQXP)
Vancouver, Canada
Year of Investment: 2013
Year of Exit: 2015-2016
IPO in March, 2014
IPO in March, 2014
Aquinox is a clinical-stage pharmaceutical company developing targeted small molecule therapeutics for the treatment of cancer and inflammatory disease.Its lead product, AQX-1125, is aselective allosteric activator of SHIP1, a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. AQX-1125 is suitable for oral, once daily dosing; it has successfully completed multiple preclinical studies and seven clinical trials, and is now advancing into Phase 3 trials in lead indication of bladder interstitial cystitis / bladder pain syndrome (IC/BPS).
For more information, please visit:
www.aqxpharma.com
For more information, please visit:
www.aqxpharma.com
Aquinox Latest News
26.05.2013
Aquinox Awarded by Canadian Biotech Industry Organization
03.04.13
Aquinox investment
Read more news
26.05.2013
Aquinox Awarded by Canadian Biotech Industry Organization
03.04.13
Aquinox investment
Read more news
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally